India caps trade margins on 137 cancer drugs, slashing prices by up to 93%

The National Pharmaceutical Pricing Authority has capped trade margins at 30% for 137 non‑scheduled anti‑cancer drugs, cutting the maximum retail price of nearly 900 brands by as much as 93%. The move lowers the MRP of many chemotherapy and targeted‑therapy medicines that previously carried high mark‑ups. Price regulation, however, may not solve the broader challenge of making comprehensive cancer care affordable for patients across the country. In a moderated conversation, Indu Bhushan – a bureaucrat, economist and the first CEO of Ayushman Bharat – and K.M. Gopakumar, a legal adviser and senior public‑health researcher, examined whether the reduced MRPs translate into real‑world affordability. Both experts noted that lower shelf prices can be offset by out‑of‑pocket expenses such as diagnostic tests, hospital stays and supportive drugs. They also highlighted the uneven distribution of price‑cut medicines in rural versus urban pharmacies. The discussion, led by journalist Bindu Shajan Perappadan, concluded that additional policy levers are needed to bridge the gap between cheaper drug labels and actual patient costs. ## Context The NPPA’s margin cap is part of India’s broader effort to control drug prices, but affordable cancer treatment typically requires coordinated insurance coverage, generic production and robust supply chains beyond price ceilings.